<DOC>
	<DOCNO>NCT02618356</DOCNO>
	<brief_summary>The primary endpoint evaluate Median disease progression free survival ( mPFS ) .</brief_summary>
	<brief_title>Combined Use Raltitrexed S-1 Treatment Patients With Metastasizing Colorectal Cancer</brief_title>
	<detailed_description>The primary endpoint evaluate disease progression free survival ( mPFS ) Raltitrexed combine S-1 treatment patient metastasize colorectal cancer fail standard chemotherapy</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>1 . ≥18 year age 2 . Histologically cytologically confirm adenocarcinoma colon rectum 3 . No systemic chemotherapy metastatic tumor 4 . ECOG ( Eastern Cooperative Oncology Group ) 01 expect survival period 3 month 5 . At least one measurable objective tumor lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 6 . ANC≥1.5*109/L；PLT≥80*109/L；HB≥90g/L；Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) ；ALB ≥ 30g/L ; Serum creatinine ≤1.5 ( ULN ) glomerular filtration rate ( GFR ) ≥60 ml/min screening within 7 day 7 . Progression within 3 month follow last administration approve standard therapy must include fluoropyrimidine , oxaliplatin irinotecan . Subjects treat oxaliplatin adjuvant setting progress within 6 month completion adjuvant therapy . Subjects progress 6 month completion oxaliplatin contain adjuvant treatment must retreat oxaliplatinbased therapy eligible . Subjects withdrawn standard treatment due unacceptable toxicity warrant discontinuation treatment preclude retreatment agent prior progression disease also allow study . Subjects may receive prior treatment Avastin ( bevacizumab ) and/or Erbitux ( cetuximab ) /Vectibix ( panitumumab ) ( KRAS WT ) 8 . Signed informed consent obtain study specific procedure . Subjects must able understand willing sign write informed consent . 1 . Prior treatment raltitrexed gimeracil oteracil potassium 2 . Systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy hormonal therapy trial within 4 week ( 6 week mitomycin C ) start receive study medication . 3 . Alcohol drug addiction 4 . Previous concurrent cancer distinct primary site histology colorectal cancer within 5 year prior randomization EXCEPT curatively treat cervical cancer situ , nonmelanoma skin cancer superficial bladder tumor [ Ta ( noninvasive tumor ) , Tis ( carcinoma situ ) T1 ( tumor invades lamina propria ) ] 5 . Any history currently know brain metastasis 6 . Multiple primary colorectal carcinoma 7 . Concomitant participation participation within last 30 day another clinical trial 8 . There important organ failure serious disease , include coronary artery disease , symptomatic cardiovascular disease myocardial infarction within 12 month ; serious neurological psychiatric history ; severe infection ; actively disseminate vascula blood coagulation . 9 . Extended field radiotherapy within 4 week limited field radiotherapy within 2 week prior randomization . Subjects must recover therapyrelated toxicity . The site previous radiotherapy evidence progressive disease site disease . 10 . Pregnant breastfeeding subject . Women childbearing potential must pregnancy test perform maximum 7 day start treatment , negative result must document start treatment . 11 . Pleural effusion ascites cause respiratory compromise ( ≥Common Terminology Criteria Adverse Events [ CTCAE ] ) Grade 2 dyspnea ) 12 . Subjects unable swallow oral medication 13 . Known history human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>